ONCOLOGY PGX PILOT EVALUATION
What our pilot study demonstrated
An operational evaluation of the Silver PGX oncology panel. Testing, interpretation, and CPIC Informed reporting and specimens. To finalized result.
22
Specimens Evaluated
How to read this pilot
12
Pharmacogenes Tested
426
Reportable Variants
100%
Workflow Completed
Key findings
All 22 specimens completed testing and generated individualized PGx reports.
Reports translated genotype findings into CPIC-informed, medication-specific guidance.
No major operational issue prevented completion of the testing and reporting workflow.
Workflow is operationally feasible and capable of producing evidence-based reports.
Designed to support safer, more individualized oncology care
The panel evaluates pharmacogenomic findings associated with oncology treatment and supportive-care medications, including findings that may inform drug selection, dose adjustment, and toxicity-risk management.
This evaluation demonstrates end-to-end laboratory workflow and report generation. Clinical outcome claims (toxicity reduction, cost-avoidance) remain supported by published literature cited on our evidence page, not by this 22-specimen operational pilot.
“Is this the right drug, at the right dose, for this patient”